Journal List > Tuberc Respir Dis > v.83(2) > 1144423

TOOLS
Lee, Ju, Kim, Kim, Yoo, Lee, Cho, Jeong, Jeon, Lee, and Kim: Risk Factor and Mortality in Patients with Pulmonary Embolism Combined with Infectious Disease
Original Article
Pulmonary Infection

Tuberculosis and Respiratory Diseases 2020; 83(2): 157-166.

Published online: 10 March 2020

DOI: https://doi.org/10.4046/trd.2019.0037

Risk Factor and Mortality in Patients with Pulmonary Embolism Combined with Infectious Disease

Gi Dong Lee, M.D.1, Sunmi Ju, M.D.2, Ju-Young Kim, M.D.3, Tae Hoon Kim, M.D., Ph.D.3, Jung-Wan Yoo, M.D.2, Seung Jun Lee, M.D., Ph.D.2, Yu Ji Cho, M.D., Ph.D.2, Yi Yeong Jeong, M.D., Ph.D.2, Kyung Nyeo Jeon, M.D., Ph.D.4, Jong Deog Lee, M.D., Ph.D.2, Ho Cheol Kim, M.D., Ph.D.3

1Department of Internal Medicine, Saint Carollo Hospital, Suncheon, Korea.

2Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Jinju, Korea.

3Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University School of Medicine, Changwon, Korea.

4Department of Diagnostic Radiology, Gyeongsang National University Changwon Hospital, Gyeongsang National University School of Medicine, Changwon, Korea.

Address for correspondence: Ho Cheol Kim, M.D., Ph.D. Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University School of Medicine, 11 Samjeongja-ro, Seongsan-gu, Changwon 51472, Korea. Phone: 82-55-214-3730, Fax: 82-55-214-8618, hockkim@gnu.ac.kr

Received 2 May 2019       Revised 24 August 2019       Accepted 21 January 2020

Copyright©2020. The Korean Academy of Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases

(open-access, http://creativecommons.org/licenses/by-nc/4.0/):

It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/)

Abstract

Background

Infectious conditions may increase the risk of venous thromboembolism. The purpose of this study was to evaluate the risk factor for combined infectious disease and its influence on mortality in patients with pulmonary embolism (PE).

Methods

Patients with PE diagnosed based on spiral computed tomography findings of the chest were retrospectively analyzed. They were classified into two groups: patients who developed PE in the setting of infectious disease or those with PE without infection based on review of their medical charts.

Results

Of 258 patients with PE, 67 (25.9%) were considered as having PE combined with infectious disease. The sites of infections were the respiratory tract in 52 patients (77.6%), genitourinary tract in three patients (4.5%), and hepatobiliary tract in three patients (4.5%). Underlying lung disease (odds ratio [OR], 3.69; 95% confidence interval [CI], 1.926–7.081; p<0.001), bed-ridden state (OR, 2.84; 95% CI, 1.390–5.811; p=0.004), and malignant disease (OR, 1.867; 95% CI, 1.017–3.425; p=0.044) were associated with combined infectious disease in patients with PE. In-hospital mortality was higher in patients with PE combined with infectious disease than in those with PE without infection (24.6% vs. 11.0%, p=0.006). In the multivariate analysis, combined infectious disease (OR, 4.189; 95% CI, 1.692–10.372; p=0.002) were associated with non-survivors in patients with PE.

Conclusion

A substantial portion of patients with PE has concomitant infectious disease and it may contribute a mortality in patients with PE.

Keywords: Pulmonary Embolism, Infectious Disease, Mortality

Introduction

Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a frequently overlooked, serious disorder1. Its incidence is increasing according to recent reports in western countries and in Korea234.
There are various well-defined risk factors of VTE, including recent major surgery, immobilization, cancer, old age, obesity, use of oral contraceptives, hormonal factors, a previous history of thrombosis, and inherited risk factors 56. In addition to known risk factors, infectious disease and the associated systemic inflammatory response may increase thrombotic events of the venous system78 caused by one or more of the three precipitants of venous thrombosis, as proposed by Virchow: venous stasis, hypercoagulability, and endothelial damage 910. Several reports have documented that the risk of VTE was increased in patients with certain infectious conditions, such as cytomegalovirus, Chlamydia pneumoniae, human immunodeficiency virus (HIV), hepatitis C virus infection, and a recent respiratory tract infection1112131415161718. Despite several reports of recent infection and VTE, its independent relationship is unclear, and clinical data regarding PE combined with infectious conditions are lacking. Therefore, the aim of the study was to evaluate the clinical characteristics and source of infection in patients with PE combined with infectious disease. And, the risk factor associated with combined infectious disease and its influence on mortality in patients with PE were assessed.

Materials and methods

1. Study design and population

Patients with PE found on computed tomography (CT) within 48 hours after admission were enrolled in this study. The study was conducted at regional university affiliated hospital (890 beds) between September 2010 and May 2014. Patients were excluded if they were admitted for pregnancy, preexisting PE or DVT, or were <18 years of age. The diagnosis of PE was confirmed based on chest findings obtained using a 64-detector CT, including enhanced CT and CT pulmonary angiogram, scanner (Brilliance-64; Philips Medical Systems, Eindhoven, Netherlands). A pulmonary radiologist assessed the existence of thrombosis in the pulmonary artery. This study was approved by the hospital's institutional review board (No. GNUCH-2018-07-001). The need for informed consent was waived because of the retrospective nature of the study.

2. Data collection and clinical outcomes

We retrospectively investigated patients' demographics, physiologic data, and laboratory data and the causes of infection, underlying diseases, and clinical outcomes. We divided patients into one of two groups based on information obtained from their medical charts: patients with PE combined with infectious disease or those with PE without infection. Patients' characteristics were compared between those two groups, and between survivors and non-survivors. Finally, we analyzed the risk factors associated with combined infectious disease in PE patients and compared mortality between those two groups. And we assessed the factor associated non-survivors in patients with PE.

3. Definition

The definition of infection was based on microbiologic data and the patient's clinical course upon medical chart review. Infection was classified according to the Centers for Disease Control and Prevention's definitions19.

4. Statistical analysis

Continuous variables are reported as the mean±standard deviation. Categorical variables are expressed as a number (%). Differences between the groups were statistically assessed using Student's t test or the chi-square test, as appropriate. Univariate and multivariate logistic regression analyses were performed to examine the risk factors for the development of infectious disease and mortality. A p-value of <0.05 was considered statistically significant in all tests. All data were analyzed using SPSS version 22.0 for Window (IBM Corp., Armonk, NY, USA).

Results

1. Patients' characteristics

Two hundred fifty-eight patients (male:female, 143:115; mean age, 68.2±13.0 years) were included. The most common symptom was dyspnea in up to 60% of patients, and 70 patients (26.9%) were asymptomatic. Twenty patients (7.7%) had a previous history of VTE, and 145 (55.8%) had an underlying malignant disease. One hundred seventy-one patients (65.8%) were older than 65 years, and 13 (5%) had a body mass index more than 30 kg/m2. Fifty-eight patients (22.3%) showed echocardiographic evidence of pulmonary hypertension, such as right ventricular hypokinesia or an increased pulmonary arterial pressure more than 20 mm Hg. The main pulmonary artery was involved in 88 patients (33.8%) based on CT findings. Thirty-seven patients (14.2%) died and the cause of death were underlying malignant disease in 27 patients (10.4%), uncontrolled infectious disease with multiorgan failure in six patients (2.3%), progression of underlying lung disease in three patients (1.1%), and heart failure in one patient (Table 1). Overall, 67 patients (25.9%) had a concomitant infectious disease. The infections involved the respiratory tract in 52 patients (77.6%), genitourinary tract in three (4.5%), hepatobiliary tract in three (4.5%), gastrointestinal tract in two (2.98%), bones and joints in three (4.5%), and other organ systems in four (5.4%) (Table 2).

2. Comparison of clinical characteristics in PE patients with infectious disease and without infection

The proportion of patients with dyspnea was greater among patients with PE combined with infectious disease than among those with PE without infection (76.1% vs. 53.9%, p<0.05). The frequency of fever was more common in patients with PE combined with infectious disease than in those with PE without infection (17.9% vs. 6.2%, p<0.05). The proportion of patients older than 65 years was higher among patients with PE combined with infectious disease than among those with PE without infection (77.6% vs. 61.7%, p<0.05). The revised Geneva score20 was not different between the two groups. The white blood cell count, serum C-reactive protein level, B-type natriuretic peptide level, and platelet count were significantly higher in patients with PE combined with infectious disease than in those with PE without underlying infection (p<0.05). The D-dimer level was not significantly different between two groups. The frequency of main pulmonary artery involvement based on CT findings was not different between PE patients with infectious disease and without infection (28% and 22.4%, respectively). The sole segmental or subsegmental pulmonary artery involvement was also not different between PE patients with infectious disease and without infection (48.7% and 55.2%, respectively). In-hospital mortality was higher in patients with PE combined with infectious disease than in those with PE without infection (22.4% vs. 11.4%, p=0.006) (Table 3).

3. Factors associated with PE combined with infectious disease

In multivariate analysis, the results showed that underlying lung disease (odds ratio [OR], 3.69; 95% confidence interval [CI], 1.926–7.081; p<0.001), bed-ridden state (OR, 2.84; 95% CI, 1.390–5.811; p=0.004), and malignant disease (OR, 1.867; 95% CI, 1.017–3.425; p=0.044) were associated with combined infectious disease in patients with PE (Table 4).

4. Comparison of clinical characteristics between survivors and non-survivors in patients with PE

The clinical characteristics and laboratory findings were compared between survivors and non-survivors in patients with PE (Table 5). The mean age and proportion of patients older than 65 years were higher in non-survivors than in survivors (p<0.05). Clinical symptoms and signs were not different between the two groups. Bed-ridden state, underlying malignant and cerebrovascular diseases were more common in non-survivors than in survivors (p<0.05). Combined infectious diseases were also common in non-survivors than in survivors (44.7% vs. 23.4%, p<0.05). The troponin-I were higher in non-survivors than in survivors (p<0.05). Radiologically, main pulmonary artery involvement was more common in non-survivors than in survivors (43.2% vs. 23.8%, p<0.05). Right ventricular hypokinesia detected by echocardiography was also more common in non-survivors than in survivors (21.6% vs. 9.9%, p<0.05).

5. Factors associated with non-survivors in patients with PE

In multivariate analysis, the result showed that age >65 years (OR, 2.575; 95% CI, 1.125–5.892; p=0.025), bed-ridden state (OR, 3.487; 95% CI, 1.397–8.703; p=0.007), malignant disease (OR, 9.275; 95% CI, 3.181–27.040; p<0.001), main pulmonary artery involvement (OR, 3.032; 95% CI, 1.283–7.162; p=0.011), and concomitant infectious disease (OR, 4.189; 95% CI, 1.692–10.372; p=0.002) were associated with non-survivors in patients of PE (Table 6).

Discussion

This study showed that a substantial portion of patients with PE had concomitant infectious disease. The underlying lung disease, bed-ridden state and malignant disease were independent risk factor for PE with combined infectious disease and presence of infectious disease may contribute mortality in patients with PE.
Several reports have shown that various infectious conditions were associated with the development of VTE, and overall, 11%–26% of patients with VTE may have an underlying acute infectious conditions2122232425. For example, cytomegalovirus antigen positivity was significantly higher in patients with VTE than in age-matched and sex-matched controls13. Additionally, in 312,147 patients with inflammatory bowel disease, the presence of VTE was 2-fold higher in patients with Clostridium difficile infection (CDI) than in those without CDI26. It has been also demonstrated that HIV infection and hepatitis virus infection are associated with an increased risk of VTE1112. In a review of a primary care database of 11,557 cases of first-time PE or VTE, Clayton et al.27 reported that a preceding respiratory infection may increase the risk of PE or VTE by more than 2.5-folds for up to a year. A prospective study of 5,451 patients with ultrasound-confirmed DVT showed that beside known risk factors, osteoarthritis, pneumonia, sepsis, and other infectious diseases were present in more than 30% of patients1. In addition, in acutely ill, hospitalized, general medical patients, the presence of acute infectious diseases was significantly associated with an increased risk of VTE (relative risk, 1.47)24. Moreover, the epidemiologic study, a case control study involving patients with a first documented VTE and controls subjects, influenza vaccination during the previous 12 months reduced the risk of VTE by about 50% in those younger than 52 years and had a similar effect on DVT and PE28. Further, when heparin was routinely administered in hospital-admitted patients with underlying infectious disease, the occurrence of non-thromboembolic events was significantly lower in these patients with various infectious diseases than in control patients with infectious diseases22.
However, it is unclear whether the infection itself increases the risk of developing VTE or whether secondary problems, such as immobility caused by infection, increase the incidence of VTE. Although the mechanism was not elucidated here, there are possible explanations for the mechanism underlying infection and VTE. Acute infectious processes may cause endothelial injury, promoting the genesis of thrombosis in the venous system, which is usually much more vulnerable to stasis than is arterial blood. From experimental study, endothelial dysfunction in vein of healthy volunteer exposed to endotoxin may increase the risk of developing cardiovascular thromboticevent10.
Respiratory tract infection was the most common cause of infection in the present study. Cohoon et al.29 reported that genitourinary and lower respiratory tract infection was the most common infections in their study. They also reported a relatively higher risk of VTE in intra-abdominal infection and blood stream infection. This is a reason why patients with lower respiratory tract infection often undergo chest CT for evaluation of the disease. Thus, PE may be detected incidentally by chest CT. The increasing incidence of chest CT is often correlated with an increasing incidence of PE, indicating that PE is incidentally detected by chest CT 3031. In this study, over two-thirds patients were diagnosed in chest CT, not embolism CT. It may indicate that PE is incidentally detected in clinical practice.
As expected, patients with PE combined with infectious conditions had a poor outcome, resulting in a higher mortality in these patients. This has not been reported previously. Other factors associated with an increased risk of mortality, such as older age, malignant disease, right ventricular dysfunction, and immobilization 3233, were similar to those identified in our study. Additionally, main pulmonary artery involvement is associated with a poor short-term outcome in patients with PE34.
This study has a several limitations. First, because of the study's retrospective design, infectious disease could not be clearly classified based on the medial record review and the exact incidence of infectious disease couldn't estimate from this study in all PE patients. Second, some proportion of patients with PE was incidentally detected by chest CT for evaluating respiratory tract infection. So, other infectious disease like intraabdominal and genitourinary tract infection may be underestimated. Third, most of patients had a severe underlying disease which may significantly contribute mortality in these patients. The adjustment of severe underlying disease needed to exact contribution of infectious disease to mortality in patients with PE.

Notes

Authors' Contributions:

  • Conceptualization: Kim HC.

  • Methodology: Lee GD, Kim HC.

  • Formal analysis: Lee GD, Kim HC.

  • Data curation: Lee GD, Kim HC.

  • Software: Lee GD, Kim HC.

  • Validation: Lee GD, Kim HC.

  • Investigation: Ju S, Kim JY, Kim TH, Yoo JW, Lee SJ, Cho YJ, Jeong YY, Jeon KN, Lee JD.

  • Writing — original draft preparation: Lee GD.

  • Writing — review and editing: Lee GD, Kim HC.

  • Approval of final manuscript: all authors.

Conflicts of Interest: No potential conflict of interest relevant to this article was reported.

Funding: No funding to declare.

References

1. Goldhaber SZ. Pulmonary embolism. Lancet. 2004; 363:1295–1305. PMID: 15094276.
crossref
2. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015; 12:464–474. PMID: 26076949.
crossref
3. Hong J, Lee JH, Yhim HY, Choi WI, Bang SM, Lee H, et al. Incidence of venous thromboembolism in Korea from 2009 to 2013. PLoS One. 2018; 13:e0191897. PMID: 29370290.
crossref
4. Jang MJ, Bang SM, Oh D. Incidence of venous thromboembolism in Korea: from the Health Insurance Review and Assessment Service database. J Thromb Haemost. 2011; 9:85–91. PMID: 20942850.
crossref
5. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003; 107(23 Suppl 1):I9–I16. PMID: 12814980.
crossref
6. Heit JA. Risk factors for venous thromboembolism. Clin Chest Med. 2003; 24:1–12. PMID: 12685052.
crossref
7. Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet. 2006; 367:1075–1079. PMID: 16581406.
crossref
8. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010; 375:657–663. PMID: 20149425.
crossref
9. Cervantes J, Rojas G. Virchow's Legacy: deep vein thrombosis and pulmonary embolism. World J Surg. 2005; 29 Suppl 1:S30–S34. PMID: 15818472.
crossref
10. Bhagat K, Moss R, Collier J, Vallance P. Endothelial “stunning” following a brief exposure to endotoxin: a mechanism to link infection and infarction? Cardiovasc Res. 1996; 32:822–829. PMID: 8944812.
crossref
11. Copur AS, Smith PR, Gomez V, Bergman M, Homel P. HIV infection is a risk factor for venous thromboembolism. AIDS Patient Care STDS. 2002; 16:205–209. PMID: 12055028.
crossref
12. Wijarnpreecha K, Thongprayoon C, Panjawatanan P, Ungprasert P. Hepatitis C virus infection and risk of venous thromboembolism: a systematic review and meta-analysis. Ann Hepatol. 2017; 16:514–520. PMID: 28611268.
crossref
13. Schimanski S, Linnemann B, Luxembourg B, Seifried E, Jilg W, Lindhoff-Last E, et al. Cytomegalovirus infection is associated with venous thromboembolism of immunocompetent adults: a case-control study. Ann Hematol. 2012; 91:597–604. PMID: 21913128.
14. Paran Y, Halutz O, Swartzon M, Schein Y, Yeshurun D, Justo D. Venous thromboembolism and cytomegalovirus infection in immunocompetent adults. Isr Med Assoc J. 2007; 9:757–758. PMID: 17987770.
15. Yildiz H, Zech F, Hainaut P. Venous thromboembolism associated with acute cytomegalovirus infection: epidemiology and predisposing conditions. Acta Clin Belg. 2016; 71:231–234. PMID: 27141959.
crossref
16. Kiser KL, Badowski ME. Risk factors for venous thromboembolism in patients with human immunodeficiency virus infection. Pharmacotherapy. 2010; 30:1292–1302. PMID: 21114396.
crossref
17. Lozinguez O, Arnaud E, Belec L, Nicaud V, Alhenc-Gelas M, Fiessinger JN, et al. Demonstration of an association between Chlamydia pneumoniae infection and venous thromboembolic disease. Thromb Haemost. 2000; 83:887–891. PMID: 10896243.
crossref
18. Koster T, Rosendaal FR, Lieuw-A-Len DD, Kroes AC, Emmerich JD, van Dissel JT. Chlamydia pneumoniae IgG seropositivity and risk of deep-vein thrombosis. Lancet. 2000; 355:1694–1695. PMID: 10905248.
crossref
19. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008; 36:309–332. PMID: 18538699.
crossref
20. Le Gal G, Righini M, Roy PM, Sanchez O, Aujesky D, Bounameaux H, et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med. 2006; 144:165–171. PMID: 16461960.
crossref
21. Gardlund B. Fatal pulmonary embolism in hospitalized nonsurgical patients. Acta Med Scand. 1985; 218:417–421. PMID: 4083084.
22. Gardlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group. Lancet. 1996; 347:1357–1361. PMID: 8637340.
23. Belch JJ, Lowe GD, Ward AG, Forbes CD, Prentice CR. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J. 1981; 26:115–117. PMID: 7291971.
crossref
24. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med. 2004; 164:963–968. PMID: 15136304.
25. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis. 2003; 14:341–346. PMID: 12945875.
26. Bhandari S, Mohammed Abdul MK, Dhakal B, Kreuziger LB, Saeian K, Stein D. Increased rate of venous thromboembolism in hospitalized inflammatory bowel disease patients with Clostridium difficile infection. Inflamm Bowel Dis. 2017; 23:1847–1852. PMID: 28837518.
crossref
27. Clayton TC, Gaskin M, Meade TW. Recent respiratory infection and risk of venous thromboembolism: case-control study through a general practice database. Int J Epidemiol. 2011; 40:819–827. PMID: 21324940.
crossref
28. Zhu T, Carcaillon L, Martinez I, Cambou JP, Kyndt X, Guillot K, et al. Association of influenza vaccination with reduced risk of venous thromboembolism. Thromb Haemost. 2009; 102:1259–1264. PMID: 19967159.
crossref
29. Cohoon KP, Ashrani AA, Crusan DJ, Petterson TM, Bailey KR, Heit JA. Is infection an independent risk factor for venous thromboembolism? A population-based, case-control study. Am J Med. 2018; 131:307–316. PMID: 28987552.
crossref
30. Winston CB, Wechsler RJ, Salazar AM, Kurtz AB, Spirn PW. Incidental pulmonary emboli detected at helical CT: effect on patient care. Radiology. 1996; 201:23–27. PMID: 8816515.
crossref
31. Dentali F, Ageno W, Becattini C, Galli L, Gianni M, Riva N, et al. Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis. Thromb Res. 2010; 125:518–522. PMID: 20451960.
crossref
32. Conget F, Otero R, Jimenez D, Marti D, Escobar C, Rodriguez C, et al. Short-term clinical outcome after acute symptomatic pulmonary embolism. Thromb Haemost. 2008; 100:937–942. PMID: 18989541.
crossref
33. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999; 353:1386–1389. PMID: 10227218.
crossref
34. Alonso Martinez JL, Anniccherico Sanchez FJ, Urbieta Echezarreta MA, Garcia IV, Alvaro JR. Central versus peripheral pulmonary embolism: analysis of the impact on the physiological parameters and long-term survival. N Am J Med Sci. 2016; 8:134–142. PMID: 27114970.
crossref
Table 1

Clinical characteristics of enrolled patients with PE

trd-83-157-i001
Clinical characteristic Value (n=258)
Demographics
 Age, yr 68.2±13.0
 Age >65 yr 171 (66.3)
 Male sex 143 (55.4)
 BMI (n=233) 22.76±3.9
 BMI >30 kg/m2 13 (5.0)
 Current smoking history 17 (6.5)
Clinical symptoms and signs
 Dyspnea 155 (60.0)
 Hemoptysis 10 (3.8)
 Fever 24 (9.3)
 Chest pain 37 (14.3)
 Lower leg edema 29 (11.2)
 Syncope 3 (1.2)
 Hypotension 15 (5.8)
 Asymptomatic 70 (27.1)
 Revised Geneva score 6.0±1.6
 Died 37 (14.3)
Risk factors
 History of recent operation (<3 mo) 67 (25.9)
 Previous history of VTE 20 (7.7)
 Presence of infectious disease 67 (25.9)
 Bed-ridden state 51 (19.7)
Comorbidities
 Malignant disease 145 (56.2)
 Cerebrovascular disease 30 (11.6)
 Lung disease 64 (24.8)
 Heart disease 9 (3.5)
 Liver disease 14 (5.4)
 Kidney disease 8 (3.1)
 Diabetes 56 (21.7)
 Hypertension 85 (32.9)
 Autoimmune disease 3 (1.2)
Laboratory findings
 WBC, mm3/L 10.6±27.8
 Platelet, mm3/L 239.2±111.5
 CRP, mg/L 51.1±62.7
 D-dimer, μg/mL (n=195) 6.6±6.3
 BNP, pg/mL (n=147) 332.7±440.0
 Troponin-I, ng/mL (n=155) 1.0±9.1
 CK-MB (n=158) 3.5±3.8
 Fibrinogen, mg/dL (n=138) 393.4±165.7
 AT III, mg/dL (n=89) 89.4±39.4
 Homocysteine, μmol/L (n=41) 9.3±5.6
Radiologic findings
 Norma chest X-ray 121 (46.8)
 Involvement of pulmonary artery on chest CT
 Main pulmonary artery, right 52 (20.2)
 Main pulmonary artery, left 39 (15.1)
 Interlobar artery, right 103 (39.9)
 Interlobar artery, left 69 (26.7)
 Segmental artery, right 158 (61.2)
 Segmental artery, left 95 (36.8)
 Subsegmental artery, right 88 (34.1)
 Subsegmental artery, left 51 (19.7)
Echocardiographic finding (n=164)
 Pulmonary hypertension 58 (22.4)
 Right ventricular hypokinesia 30 (11.6)

Values are presented as mean±SD or number (%).

BMI: body mass index; VTE: venous thromboembolism; WBC: white blood cell; CRP: C-reactive protein; BNP: B-type natriuretic peptide; CK-MB: creatine kinase-muscle/brain; AT: antithrombin; CT: computerized tomography.

Table 2

The site and cause of infection in patients with pulmonary embolism combined with infectious disease

trd-83-157-i002
Cause of infection No. (%) (n=67)
Respiratory tract infection 52 (77.6)
 Pneumonia 44 (65.6)
 Acute bronchiolitis 4 (5.9)
 Pulmonary tuberculosis 4 (5.9)
Genitourinary tract infection 3 (4.4)
Hepatobiliary tract infection 3 (4.4)
 Acute cholecystitis 1 (1.5)
 Acute pancreatitis 1 (1.5)
 Perihepatic abscess 1 (1.5)
Gastrointestinal tract infection 2 (2.9)
 Ischemic colitis 2 (2.9)
Bone and joint infection 3 (4.4)
 Osteomyelitis of spine 3 (4.4)
Skin and soft tissue infection 2 (2.9)
 Shoulder abscess 1 (1.5)
 Necrotizing fasciitis 1 (1.5)
Miscellaneous infection 2 (2.9)
 Infective endocarditis 1 (1.5)
 Tuberculous pericarditis 1 (1.5)
Table 3

Comparison of clinical characteristics in patients with PE combined with infectious disease and in patients with PE without infection

trd-83-157-i003
Variable Combined with infectious disease (n=67) Not combined with infection (n=191) p-value
Demographics
 Age, yr 71.6±12.2 67.2±13.2 0.028
 Age >65 yr 52 (77.6) 119 (62.3) 0.018
 Male sex 21 (31.3) 122 (63.9) 0.972
 BMI (n=233) 21.8±4.2 23.1±3.7 0.053
 BMI >30 kg/m2 4 (6.0) 9 (4.7) 0.458
 Current smoking history 1 (1.5) 16 (8.3) 0.208
Clinical symptoms and signs
 Dyspnea 51 (76.1) 104 (54.4) 0.002
 Hemoptysis 4 (6.0) 6 (3.1) 0.294
 Fever 12 (17.9) 12 (6.2) 0.004
 Chest pain 7 (10.4) 30 (15.7) 0.304
 Lower leg edema 7 (10.4) 22 (11.5) 0.831
 Syncope 0 (0) 3 (1.6) 0.305
 Hypotension 3 (4.5) 12 (6.2) 0.599
 Asymptomatic 15 (22.4) 55 (28.8) 0.331
 Revised Geneva score 5.9±1.6 6.1±1.5 0.302
 Died 15 (22.4) 22 (11.5) 0.027
Risk factors
 History of recent operation (<3 mo) 7 (10.4) 20 (10.4) 0.458
 Previous history of VTE 5 (7.5) 15 (7.8) 0.497
 Bed-ridden state 21 (31.3) 30 (15.7) 0.001
Comorbidities
 Malignant disease 27 (40.3) 98 (51.3) 0.343
 Cerebrovascular disease 12 (17.9) 18 (9.4) 0.012
 Lung disease 39 (58.2) 25 (13.1) 0.001
 Heart disease 9 (13.4) 29 (15.1) 0.103
 Liver disease 5 (7.5) 9 (4.7) 0.451
 Kidney disease 3 (4.5) 6 (3.1) 0.454
 Diabetes 12 (17.9) 44 (23.0) 0.402
 Hypertension 16 (23.9) 69 (36.1) 0.074
 Autoimmune disease 2 (3.0) 1 (0.5) 0.164
Laboratory findings
 WBC, mm3/L 16.4±54.0 8.6±5.4 0.048
 Platelet, mm3/L 269.3±115.4 228.7±108.4 0.013
 CRP, mg/L 69.1±63.0 44.9±61.7 0.008
 D-dimer, μg/mL (n=195) 5.9±5.9 6.9±6.5 0.299
 BNP, pg/mL (n=147) 445.8±543.7 275.0±366.3 0.025
 Troponin-I, ng/mL (n=155) 0.3±1.2 1.3 ±11.0 0.521
 CK-MB (n=158) 3.9±4.4 3.4±3.6 0.496
 Fibrinogen, mg/dL (n=138) 435.6±190.1 380.7±156.5 0.143
 AT III, mg/dL (n=89) 79.8±23.2 92.1±42.5 0.099
 Homocysteine, μmol/L (n=41) 6.5±3.6 10.1±5.9 0.042
Radiologic findings
 Norma chest X-ray 22 (32.8) 99 (51.8) 0.009
 Main pulmonary artery involvement 15 (22.4) 54 (28.3) 0.372
 Isolated segmental or subsegmental artery involvement 37 (55.2) 94 (49.2) 0.358
Echocardiographic finding (n=164)
 Pulmonary hypertension 17 (25.4) 41 (21.4) 0.484
 Right ventricular hypokinesia 6 (9.0) 24 (12.5) 0.442

Values are presented as mean±SD or number (%).

PE: pulmonary embolism; BMI: body mass index; VTE: venous thromboembolism; WBC: white blood cell; CRP: C-reactive protein; BNP: B-type natriuretic peptide; CK-MB: creatine kinase-muscle/brain; AT: antithrombin.

Table 4

Factor associated with infectious disease in patients with PE

trd-83-157-i004
Variable Univariate analysis Multivariate analysis
OR 95% CI p-value OR 95% CI p-value
Age >65 yr 2.15 1.133–4.103 0.019 1.922 0.977–3.779 0.058
BMI >30 kg/m2 1.27 0.378–4.268 0.699 - - -
Bed-ridden state 2.48 1.299–4.735 0.006 2.842 1.390–5.811 0.004
Lung disease 3.44 1.879–6.317 <0.001 3.693 1.926–7.081 0.000
Cerebrovascular disease 2.12 0.964–4.672 0.062 - - -
Malignant disease 2.331 1.321–4.111 0.003 1.867 1.017–3.425 0.044
Kidney disease 1.043 0.205–5.296 0.960 - - -
Liver disease 1.649 0.532–5.106 0.386 - - -
Diabetes 1.353 0.666–2.751 0.403 - - -

PE: pulmonary embolism; OR: odds ratio; CI: confidence interval; BMI: body mass index.

Table 5

Comparison of clinical characteristics between survivors and non-survivors in patients with PE

trd-83-157-i005
Variable Survivors (n=221) Non-survivors (n=37) p-value
Demographics
 Age, yr 62.0±15.4 69.3±12.3 0.002
 Male sex 122 (55.2) 21 (56.8) 0.817
 Age >65 yr 155 (70.1) 16 (43.2) 0.002
 BMI (n=233) 22.8±3.9 22.1±3.9 0.333
 BMI >30 kg/m2 12 (5.4) 1 (2.7) 0.552
 Current smoking history 17 (7.6) 0 (0) 0.316
Clinical symptoms and signs
 Dyspnea 129 (58.3) 26 (70.3) 0.154
 Hemoptysis 9 (4.0) 1 (2.7) 0.696
 Fever 19 (8.5) 5 (13.5) 0.331
 Chest pain 31 (14.0) 6 (16.2) 0.709
 Lower leg edema 19 (8.5) 10 (27.0) 0.001
 Syncope 3 (1.3) 0 (0) 0.478
 Hypotension 11 (5.0) 4 (10.8) 0.156
 Asymptomatic 63 (28.5) 7 (18.9) 0.236
 Revised Geneva score 6.0±1.5 6.2±1.4 0.655
Risk factors
 History of recent operation (<3 mo) 22 (9.9) 2 (5.4) 0.458
 Previous history of VTE 15 (6.8) 5 (13.2) 0.186
 Bed-ridden state 38 (17.1) 13 (35.1) 0.010
Comorbidities
 Malignant disease 114 (51.5) 31 (83.8) <0.001
 Cerebrovascular disease 27 (12.2) 3 (8.1) 0.481
 Lung disease 53 (23.9) 11 (29.7) 0.436
 Heart disease 37 (16.7) 3 (7.9) 0.225
 Liver disease 12 (5.4) 2 (5.4) 0.995
 Kidney disease 5 (2.2) 3 (8.1) 0.454
 Diabetes 48 (21.7) 8 (21.6) 0.989
 Hypertension 70 (31.6) 15 (40.5) 0.272
 Autoimmune disease 3 (1.3) 0 0.478
 Infectious disease 52 (23.5) 15 (40.5) 0.027
Laboratory findings
 WBC, mm3/L 10,521±3,001 11,197±6,334 0.765
 Platelet, mm3/L 244,257±11,322 209,354±96,246 0.052
 CRP, mg/L 48.3±62.8 68.3±60.7 0.073
 D-dimer, μg/mL (n=195) 6.69±6.29 6.75±6.65 0.964
 BNP, pg/mL (n=147) 317.5±431.4 442.9±497.5 0.320
 Troponin-I, ng/mL (n=155) 0.30±0.99 5.3±24.28 0.018
 CK-MB (n=158) 3.72±3.99 2.54±2.57 0.70
 Fibrinogen, mg/dL (n=138) 392.4±167.4 398.59±160.7 0.871
 AT III, mg/dL (n=89) 92.2±41.1 73.61±22.4 0.023
 Homocysteine, μmol/L (n=41) 9.4±5.7 7.2±3.0 0.476
Radiologic findings
 Norma chest X-ray 111 (49.8) 10 (27.0) 0.010
 Main pulmonary artery involvement 53 (23.8) 16 (43.2) 0.013
 Isolated segmental or subsegmental artery involvement 113 (50.7) 18 (48.6) 0.820
Echocardiographic finding (n=164)
 Pulmonary hypertension 49 (22.0) 9 (24.3) 0.750
 Right ventricular hypokinesia 22 (9.9) 8 (21.6) 0.038

Values are presented as mean±SD or number (%).

PE: pulmonary embolism; BMI: body mass index; VTE: venous thromboembolism; WBC: white blood cell; CRP: C-reactive protein; BNP: B-type natriuretic peptide; CK-MB: creatine kinase-muscle/brain; AT: antithrombin.

Table 6

Factors associated with non-survivors in patients with PE

trd-83-157-i006
Variable Univariate analysis Multivariate analysis
OR 95% CI p-value OR 95% CI p-value
Age >65 yr 2.992 1.471–6.086 0.002 2.575 1.125–5.892 0.025
BMI >30 kg/m2 2.087 0.263–16.547 0.486 - - -
Bed-ridden state 2.637 1.233–5.638 0.012 3.487 1.397–8.703 0.007
Lung disease 1.357 0.629–2.929 0.437 - - -
Cerebrovascular disease 1.561 0.449–5.434 0.484 - - -
Malignant disease 4.940 1.983–12.306 0.001 9.275 3.181–27.040 0.000
Kidney disease 3.847 0.879–16.837 0.074 - - -
Liver disease 1.005 0.216–4.683 0.995 - - -
Diabetes 1.006 0.432–2.342 0.989 - - -
Infectious disease 2.242 1.085–4.634 0.029 4.189 1.692–10.372 0.002
Hypotension 2.336 0.702–7.769 0.166 - - -
Troponin-I 1.045 0.958–1.141 0.319 - - -
Main pulmonary artery involvement 2.444 1.190–5.020 0.015 3.032 1.283–7.162 0.011
Right ventricular hypokinesia 2.520 1.027–6.187 0.044 1.997 0.696–5.735 0.199

PE: pulmonary embolism; OR: odds ratio; CI: confidence interval; BMI: body mass index.

TOOLS
Similar articles